Boston Scientific now expects PFA to likely exceed its previously communicated range of 40% to 60% ... WATCHMAN, a Long-Term Growth Driver: Boston Scientific’s structural heart programs are ...

Boston Scientifics FARAPULSE PFA System is approved for pulmonary vein isolation (PVI) in patients who have paroxysmal AF, a condition that manifests itself in the form of an irregular heartbeat.

Boston Scientific has announced the approval of its Farapulse pulsed field ablation (PFA) system by the Pharmaceuticals and Medical Device Agency (PMDA) in Japan. This system is a new option for ...

Boston Scientific delivered strong first-quarter results, building on its hefty performance seen in 2024, as adoption of Farapulse and Watchman have impressed. Why it matters: Boston has exceeded ...

Watching The Watchman. Not as large as the PFA market, the LAAC market is nevertheless highly significant to Boston Scientific, due at least in part to the fact that BSX has a very strong share ...

Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17. In late-breaking data presentations, the ADVANTAGE AF trial for the ...

In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report), with a price target of $100.00. Don't Miss our Black ...

Boston Scientific now expects PFA to likely exceed its previously communicated range of 40% to 60% ... WATCHMAN, a Long-Term Growth Driver: Boston Scientific’s structural heart programs are ...

US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients with paroxysmal atrial fibrillation (AF) as the company looks to ...